Urology · Youngstown, OH
NPI
1457493231
Since 2007
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
602 Parmalee Ave, Suite 300
Youngstown, OH, 44510
Phone (330) 744-2272
Groups this clinician bills Medicare through
Medicare paid, 2024
$254K
4,474 services
Medicare patients, 2024
1,035
Average age 75
Drug cost, 2024
$1.8M
4,144 prescriptions
Company payments, 2025
$7,186
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark A Memo was code 99490 (chronic, principal, and transitional care management), 1,043 times for 184 patients. In total Mark A Memo billed 4,474 services in 85 codes, and Medicare paid $254K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-04-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,043 | 184 | $44.44 | $46K |
| 81002 Clinical Chemistry | Office | 806 | 593 | $3.41 | $2,746 |
| 99214 Office E&M - Established | Office | 423 | 360 | $83.91 | $35K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 320 | 291 | $12.31 | $3,941 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 207 | 32 | $141.94 | $29K |
| 99213 Office E&M - Established | Office | 187 | 173 | $53.32 | $9,971 |
| 51798 Ultrasound - Nonspecific | Office | 162 | 148 | $7.37 | $1,195 |
| 36415 Venipuncture Blood Collection | Office | 140 | 134 | $8.59 | $1,202 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 133 | 36 | $43.91 | $5,840 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 98 | 63 | $34.56 | $3,386 |
| 52000 Cystourethroscopy | Office | 90 | 82 | $154.14 | $14K |
| 99215 Office E&M - Established | Office | 89 | 67 | $117.02 | $10K |
| 99204 Office E&M - New | Office | 86 | 86 | $99.62 | $8,567 |
| 99222 Hospital E&M - Initial | Facility | 67 | 65 | $98.56 | $6,603 |
| 74420 Standard X-ray | Facility | 44 | 42 | $18.07 | $795 |
By year: 2022 $220K for 3,288 services; 2023 $233K for 3,684 services; 2024 $254K for 4,474 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 806 | 593 | $3.41 | $2,746 |
| 36415 Venipuncture Blood Collection | 140 | 134 | $8.59 | $1,202 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark A Memo prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,106 prescriptions and refills. In total Mark A Memo wrote 4,144 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,106 | 2,549 | 300 | $15K |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 480 | 480 | 261 | $4,213 |
| Finasteride Generic | 361 | 930 | 104 | $4,506 |
| Oxybutynin Chloride Generic | 333 | 627 | 93 | $6,250 |
| Ciprofloxacin Hcl Generic | 254 | 254 | 174 | $1,054 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 229 | 243 | 84 | $661 |
| Myrbetriq Mirabegron | 222 | 324 | 52 | $144K |
| Gemtesa Vibegron | 145 | 211 | 42 | $102K |
| Cephalexin Generic | 142 | 142 | 92 | $375 |
| Orgovyx Relugolix | 131 | 131 | 16 | $354K |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 74 | 96 | 23 | $1,722 |
| Xtandi Enzalutamide | 67 | 67 | 14 | $867K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 56 | 161 | 23 | $987 |
| Desmopressin Acetate Generic | 51 | 63 | Under 11 | $2,285 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 37 | 37 | 34 | $104 |
Brand drugs: - claims; generic drugs: 3,357 claims; opioid claims: 40.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark A Memo $7,186 ($7,186 in general payments such as food, travel and fees) from 25 companies. The largest payer was Avyxa Pharma, LLC with $3,492.
| Company | Payments | Amount |
|---|---|---|
| Avyxa Pharma, LLC | 7 | $3,492 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $1,216 |
| Medtronic, Inc. MDT | 31 | $1,206 |
| Immunitybio, Inc. IBRX | 3 | $197 |
| Dendreon Pharmaceuticals LLC | 4 | $153 |
| Calyxo, Inc. | 1 | $130 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $94.75 |
| Pfizer Inc. PFE | 4 | $77.09 |
| Sumitomo Pharma America, Inc. 4506.T | 4 | $75.11 |
| Verity Pharmaceuticals Inc. | 3 | $64.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.